Fundz

Passage Bio, Inc. announced it raised $110 Million in an initial filing from an offering of $110 Million

PUBLIC · PASGSep 06, 2019

Amount Raised

$110 Million

Round Type

Venture

United StatesBiotechnologyHealthcareHealth CareGeneticsTherapeutics

Company Information

Company

Passage Bio

Location

United States

About

Passage Bio, Inc. (NASDAQ: PASG) is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases.

Fundz sees it the moment Passage Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsWill C., Chief Executive Officer hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Passage Bio's next move

See what Strategic adds

Passage Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.